Неалкогольная жировая болезнь печени и энтеральная недостаточность: коморбидность их развития - Журнал Терапевтический архив № 12 Vario 2019
Неалкогольная жировая болезнь печени и энтеральная недостаточность: коморбидность их развития
Вахрушев Я.М., Сучкова Е.В., Лукашевич А.П. Неалкогольная жировая болезнь печени и энтеральная недостаточность: коморбидность их развития. Терапевтический архив. 2019; 91 (12): 84–89. DOI: 10.26442/00403660.2019.12.000134
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье отражены современные литературные данные по эпидемиологии и факторам риска неалкогольной жировой болезни печени (НАЖБП). Важным аспектом является описание современных взглядов сочетанного поражения гепатобилиарного тракта и тонкой кишки. Особая роль в развитии НАЖБП отводится нарушениям кишечной микробиоты. Показано значение энтерогепатической циркуляции желчных кислот в развитии заболеваний кишечника и печени. Представляется актуальным дальнейшее изучение коморбидности развития НАЖБП и энтеропатии для разработки патогенетически обоснованной терапии.
Ключевые слова: неалкогольная жировая болезнь печени, тонкая кишка, синдром избыточного бактериального роста, желчные кислоты, липополисахарид.
Keywords: non-alcoholic fatty liver disease, small intestine, bacterial overgrowth syndrome, bile acids, lipopolysaccharide.
Ключевые слова: неалкогольная жировая болезнь печени, тонкая кишка, синдром избыточного бактериального роста, желчные кислоты, липополисахарид.
________________________________________________
Keywords: non-alcoholic fatty liver disease, small intestine, bacterial overgrowth syndrome, bile acids, lipopolysaccharide.
Список литературы
1. Drapkina O, Ivashkin V. Prevalence of Non-alcoholic Fatty Liver Disease in the Russian Federation: the Open, Multicenter, Prospective Study, DIREG 1. Clin Med Res. 2015;3(2):31-6. doi: 10.12691/ajcmr-3-2-3
2. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Клинические перспективы гастроэнтерологии, гепатологии. 2012;(1):3-9 [Ivashkin VT, Mayevskaya MV, Pavlov ChS. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2012;(1):3-9 (In Russ.)].
3. De Alwis NM, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(1):104-12. doi: 10.1016/j.jhep.2008.01.009
4. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:6891. doi: 10.1136/bmj.d6891
5. Tacuma Y, Nouso Y. Nonalcoholic steatohepatitis associated hepatocellular carcinoma: our case series and literature review. Wld J Gastroenterol. 2010;16(12):1436-41. doi: 10.3748/wjg.v16.i12.1436
6. Waly RS, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus of different aspects of management. ISRN Oncol. 2012;2012:1-12. doi: 10.5402/2012/421673
7. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342. doi: 10.1016/ j.cgh.2012.10.001
8. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24(4):899-919. doi: 10.1016/j.idc.2010.07.004
9. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371. doi: 10.1016/j.jhep.2009.03.019
10. McCullough AJ. The epidemiology and risk factors of NASH. Hepatology. 2013;58(5):1644-54. doi: 10.1002/9780470987438.ch3
11. Duvnjak M, Lerotic I, Barsic N. Patogenesis and management issues for non-alcoholik fatty liver disease. World J Gastroenterol. 2007;13(34):4539-50. doi: 10.3748/wjg.v13.i34.4539
12. Atabek ME. Non-alcoholic fatty liver disease and metabolic syndrome in obese children. J Gastroenterol. 2011;17(39):4445. doi: 10.3748/wjg.v17.i39.4445
13. Ahmed A, Perumpail RB, Harrison SA. Hige prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? Hepatology. 2016;63(1):20-2. doi: 10.1002/hep.28277
14. Gerskowitch VP, Hodge J, Hull RAD, Shankley NP, Kalindjian SB, McEwen J, Black JW. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol. 2007;63(5):618-22. doi: 10.1111/j.1365-2125.2006.02789.x
15. Williamson RM, Price JF, Glance S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-44. doi: 10.2337/dc10-2229
16. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hoffich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015;43(1):83-95. doi: 10.1111/apt.13405
17. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Kechagias S, Hultcrantz R. Fibrosis Stage is the strongest predictor for disease-specific mortality in NAFLD After Up to 33 Years of Follow-Up. Hepatology. 2015;61(5):1547-54. doi: 10.1016/j.jhep.2015.11.004
18. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progress tu hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436-43. doi: 10.1002/ijc.25797
19. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-90. doi: 10.1038/nrgastro.2013.171
20. Michelotti GA, Machado MV. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-60. doi: 10.1038/nrgastro.2013.183
21. Stickel F, Hellerbrand С. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303-7. doi: 10.1136/gut.2009.199661
22. Подымова С.Д. Болезни печени: руководство для врачей. Изд. 5-е, перераб. и доп. М.: МИА, 2018 [Podymova SD. Liver disease: a guide for physicians. 5th ed. Moscow: MIA, 2018 (In Russ.)].
23. Younossi ZM, Koenig AB, Abdelatif DA, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assement of prevalence, incidence and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
24. Copaci I, Mindrut E, Micu L, Hortopan M, Voiculescu M. Can disease progression in non-alcoholic steatohepatitis be stopped? J Hepatol. 2009;50(1):S358. doi: 10.1016/s0168-8278(09)60989-2
25. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381
26. Rolfe LD. Interactions among microorganisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis. 1984;6(1):73-9. doi: 10.1093/clinids/6.Supplement_1.S73
27. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fang SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-7. doi: 10.1002/hep.26319
28. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2012;57:601-9. doi: 10.1002/hep.26093
29. Erejuwa OO, Sulaiman SA, Wahab MSW. Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci. 2014;15:4158-88. doi: 10.3390/ijms15034158
30. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germfree mice. Proc Natl Acad Sci USA. 2007;104:979-84. doi: 10.1073/pnas.0605374104
31. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumor necrosis factor-alfa in a pathogenesis of nonalcoholic steatohepatitis. Gut. 2001;48:206-11. doi: 10.1136/gut.48.2.206
32. Wieland A, Frank DN, Harnke B, Bambha A. Systematic review: microbial dysbiosis and nonalcoholic fatty liver desease. Aliment Pharmacol Ther. 2015;42(9):1051-63. doi: 10.1111/apt.13376
33. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29(3):264-70. doi:10.1097/mog.0b013e32835ff948
34. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One. 2012;7(10):e47713. doi: 10.1371/journal.pone.0047713
35. Rivera CA, Adegboyega PN, van Rooijen N, Tagalicud A., Allman M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47(4):571-9. doi: 1016/j.hep.2007.04/019
36. Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. Curr Opin Lipidol. 2008;19(3):223-34. doi: 10.1097/MOL.0b013e3282fee935
37. Buchman AL, Dubin MD, Moucarzel AA, Jenden DJ, Roch M, Rice KM, Gornbein J, Ament ME. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology. 1995;22:1399-403. doi: 10.1016/0270–9139(95)90143-4
38. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012;28(2):159-65. doi: 10.1097/MOG.0b013e32834e7b4b
39. Csak T, Velayudham A, Hritz I, Petrasek J, Levin L, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E, Szabo G. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2001;300(3):433-41. doi: 10.1152/ajpgi.00163.2009
40. Селиверстов П., Радченко В., Сафроненкова И., Ситкин С. Взаимоотношения печени и кишечника на фоне дисбаланса микрофлоры толстой кишки. Врач. 2009;(10):27-31 [Seliverstov P, Radchenko V, Safronenkova I, Sitkin S. Liver-intestine relationships in colonic microflora dysbalance. Vrach. 2009;(10):27-31 (In Russ.)].
41. Вахрушев Я.М., Лукашевич А.П. Особенности нарушений пищеварения, всасывания и микробиоценоза в кишечнике у больных желчнокаменной болезнью. Терапевтический архив. 2017;(2):28-32 [Vakhrushev YaM, Lukashevich АР. Specific features of impaired intestinal digestion, absorption, and microbiocenosis in patients with cholelithiasis. Therapeutic Archive. 2017;(2):28-32 (In Russ.)]. doi: 10.17116/terarkh201789228-32
43. Al-Attas O, Al-Daghri N, Al-Rubeaan K. Changes in endotoxin levels in T2DM subjects on antidiabetic therapias. Cardiovasc Diabet. 2009;8:20-29. doi: 10.1186/1475-2840-8-20
44. Rodes N, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics Lactobacillus and Bifidobacteriumon gut-derived lypopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013;23:518-26. doi: 10.4014/jmb.1205.05018
45. Arumugam M, Raes J, Pelletier Е, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80. doi: 10.1038/nature09944
46. Селиверстов П.В., Ситкин С.И., Радченко В.Г. Роль дисбиоза кишечника в развитии митохондриальной дисфункции и неалкогольной жировой болезни печени. Медицинский совет. Гастроэнтерология. 2018;(6):90-5 [Seliverstov PV, Sitkin SI, Radchenko VG. The role of intestinal disbiosis in the development of mitochondrial dysfunction and nonalcoholic fatty liver disease. Meditsinskii sovet. Gastroenterologiya. 2018;(6):90-5 (In Russ.)]. doi: 10.21518/2079-701X-2018-6-89-95
47. Немцов Л.М. Синдром избыточного бактериального роста в кишечнике при заболеваниях печени. Здравоохранение. 2015;(4):26-34 [Nemtsov LM. Syndrome of bacteria overgrowth under liver diseases. Zdravookhranenie. 2015;(4):26-34 (In Russ.)].
48. Fuchs C, Claudel T, Trauner M. Bile acid-mediated control of liver triglycerides. Semin Liver Dis. 2013;33(4):330-42. doi: 10.1055/s-0033-1358520
49. Conradas VM, Jorens PJ, De Clerck LS, Van Saene HK, Ieven MM, Bosmans JM, Schuerwegh A, Bridts CH, Wuyts F, Stevens WJ, Anker SD, Rauchhaus M, Vrints CJ. Selectiv intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail. 2004;6(4):483-91. doi: org/10.1016/j.ejheart.2003.12.004
50. Вахрушев Я.М., Горбунов А.Ю., Тронина Д.В., Сучкова Е.В., Ляпина М.В., Хохлачева Н.А. Желчнокаменная болезнь как возможное проявление системной патологии органов пищеварения. Терапевтический архив. 2015;87(2):54-8 [Vakhrushev YaM, Gorbunov AYu, Tronina DV, Suchkova EV, Liapina MV, Khokhlacheva NA. Cholelithiasis as a possible manifestation of systemic digestive diseases. Therapeutic Archive. 2015;87(2):54-8 (In Russ.)]. doi: 10.17116/terarkh201587254-58
51. Hylemon PB, Zhou HP, Pandak WM, Ren SL, Git G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50(8):1509-20. doi: 10.1194/jlr.R900007-JLR200
52. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor – A molecular link between bile acid and glucose metabolism. Arterioscler Thromb Vasc. 2005;25(10):2020-31. doi: 10.1161/01.ATV.0000178994.21828.a7
53. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1-2):17-29. doi: 10.1061/j.mce.2012.05.004
54. Sayin SI, Wahlstrom A, Felin J, Jantty S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the levels of Tauro-β-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab. 2013;368(1-2):17-29. doi: 10.1061/j.cmet.2013.01.003
55. Li F, Jiang CT, Krauze KW, Li YF, Albert I, Hao HP, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodeling leads tu inhibition of intestinal farnesoid X receptor signaling and decreased obesity. Nat Commun. 2013;4:2384. doi: 10.1038/ncomms.3384
56. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci. 2006;103(4):1006-11. doi: 10.1073/pnas.0506982103
57. Маевская Е.А., Черемушкин С.В., Кривобородова Н.А., Кучерявый Ю.А. Синдром избыточного бактериального роста в тонкой кишке: от последних научных данных к рутинной практике. Клинические перспективы гастроэнтерологии, гепатологии. 2013;(5):29-40 [Mayevskaya YeA, Cheremushkin SV, Krivoborodova NA, Kucheryavy YuA. Small-intestinal bacterial overgrowth syndrome: from recent scientific data to everyday practice. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2013;(5):29-40 (In Russ.)].
58. Ильченко А.А. Болезни желчного пузыря и желчных путей: руководство для врачей. М.: МИА, 2011 [Il'chenko A.A. Diseases of the gallbladder and biliary tract: a guide for physicians. Moscow: MIA, 2011 (In Russ.)].
59. Вахрушев Я.М., Лукашевич А.П., Горбунов А.Ю., Пенкина И.А. Интестинальные механизмы в нарушении энтерогепатической циркуляции желчных кислот при желчнокаменной болезни. Вестник Российской академии медицинских наук. 2017;72(2):105-11 [Vakhrushev YaM, Lukashevich AP, Gorbunov AYu, Penkina IA. Intestinal Mechanisms of Enterohepatic Circulation Disturbance of Bile Acids in Cholelithiasis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2017;72(2):105-11 (In Russ.)]. doi: 10.15690/vramn807
60. Савельев В.С., Петухов В.А. Желчнокаменная болезнь и синдром нарушенного пищеварения. М.: Боргес, 2011 [Savel'ev VS, Petukhov VA. Gallstone disease and indigestion syndrome. Moscow: Borges, 2011 (In Russ.)].
61. Чукаева И.И., Самородская И.В., Ларина В.Н. Сочетанная патология: дискуссионные вопросы терминологии, учета и влияния на выбор тактики ведения пациента. Терапевтический архив. 2018;90(8):125-30 [Chukayeva II, Samorodskaya IV, Larina VN. The prevalence of multimorbidity: discussion about the terminology, registration and its effect on patient’s health care utilization. Therapeutic Archive. 2018;90(8):125-30 (In Russ.)]. doi: 10.26442/terarkh2018908125-130
2. [Ivashkin VT, Mayevskaya MV, Pavlov ChS. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2012;(1):3-9 (In Russ.)].
3. De Alwis NM, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(1):104-12. doi: 10.1016/j.jhep.2008.01.009
4. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:6891. doi: 10.1136/bmj.d6891
5. Tacuma Y, Nouso Y. Nonalcoholic steatohepatitis associated hepatocellular carcinoma: our case series and literature review. Wld J Gastroenterol. 2010;16(12):1436-41. doi: 10.3748/wjg.v16.i12.1436
6. Waly RS, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus of different aspects of management. ISRN Oncol. 2012;2012:1-12. doi: 10.5402/2012/421673
7. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342. doi: 10.1016/ j.cgh.2012.10.001
8. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24(4):899-919. doi: 10.1016/j.idc.2010.07.004
9. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371. doi: 10.1016/j.jhep.2009.03.019
10. McCullough AJ. The epidemiology and risk factors of NASH. Hepatology. 2013;58(5):1644-54. doi: 10.1002/9780470987438.ch3
11. Duvnjak M, Lerotic I, Barsic N. Patogenesis and management issues for non-alcoholik fatty liver disease. World J Gastroenterol. 2007;13(34):4539-50. doi: 10.3748/wjg.v13.i34.4539
12. Atabek ME. Non-alcoholic fatty liver disease and metabolic syndrome in obese children. J Gastroenterol. 2011;17(39):4445. doi: 10.3748/wjg.v17.i39.4445
13. Ahmed A, Perumpail RB, Harrison SA. Hige prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? Hepatology. 2016;63(1):20-2. doi: 10.1002/hep.28277
14. Gerskowitch VP, Hodge J, Hull RAD, Shankley NP, Kalindjian SB, McEwen J, Black JW. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol. 2007;63(5):618-22. doi: 10.1111/j.1365-2125.2006.02789.x
15. Williamson RM, Price JF, Glance S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-44. doi: 10.2337/dc10-2229
16. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hoffich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015;43(1):83-95. doi: 10.1111/apt.13405
17. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Kechagias S, Hultcrantz R. Fibrosis Stage is the strongest predictor for disease-specific mortality in NAFLD After Up to 33 Years of Follow-Up. Hepatology. 2015;61(5):1547-54. doi: 10.1016/j.jhep.2015.11.004
18. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progress tu hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436-43. doi: 10.1002/ijc.25797
19. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-90. doi: 10.1038/nrgastro.2013.171
20. Michelotti GA, Machado MV. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-60. doi: 10.1038/nrgastro.2013.183
21. Stickel F, Hellerbrand С. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303-7. doi: 10.1136/gut.2009.199661
22. [Podymova SD. Liver disease: a guide for physicians. 5th ed. Moscow: MIA, 2018 (In Russ.)].
23. Younossi ZM, Koenig AB, Abdelatif DA, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assement of prevalence, incidence and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
24. Copaci I, Mindrut E, Micu L, Hortopan M, Voiculescu M. Can disease progression in non-alcoholic steatohepatitis be stopped? J Hepatol. 2009;50(1):S358. doi: 10.1016/s0168-8278(09)60989-2
25. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381
26. Rolfe LD. Interactions among microorganisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis. 1984;6(1):73-9. doi: 10.1093/clinids/6.Supplement_1.S73
27. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fang SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-7. doi: 10.1002/hep.26319
28. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2012;57:601-9. doi: 10.1002/hep.26093
29. Erejuwa OO, Sulaiman SA, Wahab MSW. Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci. 2014;15:4158-88. doi: 10.3390/ijms15034158
30. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germfree mice. Proc Natl Acad Sci USA. 2007;104:979-84. doi: 10.1073/pnas.0605374104
31. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumor necrosis factor-alfa in a pathogenesis of nonalcoholic steatohepatitis. Gut. 2001;48:206-11. doi: 10.1136/gut.48.2.206
32. Wieland A, Frank DN, Harnke B, Bambha A. Systematic review: microbial dysbiosis and nonalcoholic fatty liver desease. Aliment Pharmacol Ther. 2015;42(9):1051-63. doi: 10.1111/apt.13376
33. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29(3):264-70. doi:10.1097/mog.0b013e32835ff948
34. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One. 2012;7(10):e47713. doi: 10.1371/journal.pone.0047713
35. Rivera CA, Adegboyega PN, van Rooijen N, Tagalicud A., Allman M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47(4):571-9. doi: 1016/j.hep.2007.04/019
36. Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. Curr Opin Lipidol. 2008;19(3):223-34. doi: 10.1097/MOL.0b013e3282fee935
37. Buchman AL, Dubin MD, Moucarzel AA, Jenden DJ, Roch M, Rice KM, Gornbein J, Ament ME. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology. 1995;22:1399-403. doi: 10.1016/0270–9139(95)90143-4
38. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012;28(2):159-65. doi: 10.1097/MOG.0b013e32834e7b4b
39. Csak T, Velayudham A, Hritz I, Petrasek J, Levin L, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E, Szabo G. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2001;300(3):433-41. doi: 10.1152/ajpgi.00163.2009
40. [Seliverstov P, Radchenko V, Safronenkova I, Sitkin S. Liver-intestine relationships in colonic microflora dysbalance. Vrach. 2009;(10):27-31 (In Russ.)].
41. [Vakhrushev YaM, Lukashevich АР. Specific features of impaired intestinal digestion, absorption, and microbiocenosis in patients with cholelithiasis. Therapeutic Archive. 2017;(2):28-32 (In Russ.)]. doi: 10.17116/terarkh201789228-32
43. Al-Attas O, Al-Daghri N, Al-Rubeaan K. Changes in endotoxin levels in T2DM subjects on antidiabetic therapias. Cardiovasc Diabet. 2009;8:20-29. doi: 10.1186/1475-2840-8-20
44. Rodes N, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics Lactobacillus and Bifidobacteriumon gut-derived lypopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013;23:518-26. doi: 10.4014/jmb.1205.05018
45. Arumugam M, Raes J, Pelletier Е, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80. doi: 10.1038/nature09944
46. [Seliverstov PV, Sitkin SI, Radchenko VG. The role of intestinal disbiosis in the development of mitochondrial dysfunction and nonalcoholic fatty liver disease. Meditsinskii sovet. Gastroenterologiya. 2018;(6):90-5 (In Russ.)]. doi: 10.21518/2079-701X-2018-6-89-95
47. [Nemtsov LM. Syndrome of bacteria overgrowth under liver diseases. Zdravookhranenie. 2015;(4):26-34 (In Russ.)].
48. Fuchs C, Claudel T, Trauner M. Bile acid-mediated control of liver triglycerides. Semin Liver Dis. 2013;33(4):330-42. doi: 10.1055/s-0033-1358520
49. Conradas VM, Jorens PJ, De Clerck LS, Van Saene HK, Ieven MM, Bosmans JM, Schuerwegh A, Bridts CH, Wuyts F, Stevens WJ, Anker SD, Rauchhaus M, Vrints CJ. Selectiv intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail. 2004;6(4):483-91. doi: org/10.1016/j.ejheart.2003.12.004
50. [Vakhrushev YaM, Gorbunov AYu, Tronina DV, Suchkova EV, Liapina MV, Khokhlacheva NA. Cholelithiasis as a possible manifestation of systemic digestive diseases. Therapeutic Archive. 2015;87(2):54-8 (In Russ.)]. doi: 10.17116/terarkh201587254-58
51. Hylemon PB, Zhou HP, Pandak WM, Ren SL, Git G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50(8):1509-20. doi: 10.1194/jlr.R900007-JLR200
52. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor – A molecular link between bile acid and glucose metabolism. Arterioscler Thromb Vasc. 2005;25(10):2020-31. doi: 10.1161/01.ATV.0000178994.21828.a7
53. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1-2):17-29. doi: 10.1061/j.mce.2012.05.004
54. Sayin SI, Wahlstrom A, Felin J, Jantty S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the levels of Tauro-β-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab. 2013;368(1-2):17-29. doi: 10.1061/j.cmet.2013.01.003
55. Li F, Jiang CT, Krauze KW, Li YF, Albert I, Hao HP, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodeling leads tu inhibition of intestinal farnesoid X receptor signaling and decreased obesity. Nat Commun. 2013;4:2384. doi: 10.1038/ncomms.3384
56. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci. 2006;103(4):1006-11. doi: 10.1073/pnas.0506982103
57. [Mayevskaya YeA, Cheremushkin SV, Krivoborodova NA, Kucheryavy YuA. Small-intestinal bacterial overgrowth syndrome: from recent scientific data to everyday practice. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2013;(5):29-40 (In Russ.)].
58.[Il'chenko A.A. Diseases of the gallbladder and biliary tract: a guide for physicians. Moscow: MIA, 2011 (In Russ.)].
59. [Vakhrushev YaM, Lukashevich AP, Gorbunov AYu, Penkina IA. Intestinal Mechanisms of Enterohepatic Circulation Disturbance of Bile Acids in Cholelithiasis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2017;72(2):105-11 (In Russ.)]. doi: 10.15690/vramn807
60. [Savel'ev VS, Petukhov VA. Gallstone disease and indigestion syndrome. Moscow: Borges, 2011 (In Russ.)].
61. [Chukayeva II, Samorodskaya IV, Larina VN. The prevalence of multimorbidity: discussion about the terminology, registration and its effect on patient’s health care utilization. Therapeutic Archive. 2018;90(8):125-30 (In Russ.)]. doi: 10.26442/terarkh2018908125-130
2. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Клинические перспективы гастроэнтерологии, гепатологии. 2012;(1):3-9 [Ivashkin VT, Mayevskaya MV, Pavlov ChS. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2012;(1):3-9 (In Russ.)].
3. De Alwis NM, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(1):104-12. doi: 10.1016/j.jhep.2008.01.009
4. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:6891. doi: 10.1136/bmj.d6891
5. Tacuma Y, Nouso Y. Nonalcoholic steatohepatitis associated hepatocellular carcinoma: our case series and literature review. Wld J Gastroenterol. 2010;16(12):1436-41. doi: 10.3748/wjg.v16.i12.1436
6. Waly RS, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus of different aspects of management. ISRN Oncol. 2012;2012:1-12. doi: 10.5402/2012/421673
7. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342. doi: 10.1016/ j.cgh.2012.10.001
8. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24(4):899-919. doi: 10.1016/j.idc.2010.07.004
9. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371. doi: 10.1016/j.jhep.2009.03.019
10. McCullough AJ. The epidemiology and risk factors of NASH. Hepatology. 2013;58(5):1644-54. doi: 10.1002/9780470987438.ch3
11. Duvnjak M, Lerotic I, Barsic N. Patogenesis and management issues for non-alcoholik fatty liver disease. World J Gastroenterol. 2007;13(34):4539-50. doi: 10.3748/wjg.v13.i34.4539
12. Atabek ME. Non-alcoholic fatty liver disease and metabolic syndrome in obese children. J Gastroenterol. 2011;17(39):4445. doi: 10.3748/wjg.v17.i39.4445
13. Ahmed A, Perumpail RB, Harrison SA. Hige prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? Hepatology. 2016;63(1):20-2. doi: 10.1002/hep.28277
14. Gerskowitch VP, Hodge J, Hull RAD, Shankley NP, Kalindjian SB, McEwen J, Black JW. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol. 2007;63(5):618-22. doi: 10.1111/j.1365-2125.2006.02789.x
15. Williamson RM, Price JF, Glance S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-44. doi: 10.2337/dc10-2229
16. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hoffich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015;43(1):83-95. doi: 10.1111/apt.13405
17. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Kechagias S, Hultcrantz R. Fibrosis Stage is the strongest predictor for disease-specific mortality in NAFLD After Up to 33 Years of Follow-Up. Hepatology. 2015;61(5):1547-54. doi: 10.1016/j.jhep.2015.11.004
18. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progress tu hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436-43. doi: 10.1002/ijc.25797
19. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-90. doi: 10.1038/nrgastro.2013.171
20. Michelotti GA, Machado MV. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-60. doi: 10.1038/nrgastro.2013.183
21. Stickel F, Hellerbrand С. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303-7. doi: 10.1136/gut.2009.199661
22. Подымова С.Д. Болезни печени: руководство для врачей. Изд. 5-е, перераб. и доп. М.: МИА, 2018 [Podymova SD. Liver disease: a guide for physicians. 5th ed. Moscow: MIA, 2018 (In Russ.)].
23. Younossi ZM, Koenig AB, Abdelatif DA, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assement of prevalence, incidence and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
24. Copaci I, Mindrut E, Micu L, Hortopan M, Voiculescu M. Can disease progression in non-alcoholic steatohepatitis be stopped? J Hepatol. 2009;50(1):S358. doi: 10.1016/s0168-8278(09)60989-2
25. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381
26. Rolfe LD. Interactions among microorganisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis. 1984;6(1):73-9. doi: 10.1093/clinids/6.Supplement_1.S73
27. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fang SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-7. doi: 10.1002/hep.26319
28. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2012;57:601-9. doi: 10.1002/hep.26093
29. Erejuwa OO, Sulaiman SA, Wahab MSW. Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci. 2014;15:4158-88. doi: 10.3390/ijms15034158
30. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germfree mice. Proc Natl Acad Sci USA. 2007;104:979-84. doi: 10.1073/pnas.0605374104
31. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumor necrosis factor-alfa in a pathogenesis of nonalcoholic steatohepatitis. Gut. 2001;48:206-11. doi: 10.1136/gut.48.2.206
32. Wieland A, Frank DN, Harnke B, Bambha A. Systematic review: microbial dysbiosis and nonalcoholic fatty liver desease. Aliment Pharmacol Ther. 2015;42(9):1051-63. doi: 10.1111/apt.13376
33. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29(3):264-70. doi:10.1097/mog.0b013e32835ff948
34. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One. 2012;7(10):e47713. doi: 10.1371/journal.pone.0047713
35. Rivera CA, Adegboyega PN, van Rooijen N, Tagalicud A., Allman M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47(4):571-9. doi: 1016/j.hep.2007.04/019
36. Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. Curr Opin Lipidol. 2008;19(3):223-34. doi: 10.1097/MOL.0b013e3282fee935
37. Buchman AL, Dubin MD, Moucarzel AA, Jenden DJ, Roch M, Rice KM, Gornbein J, Ament ME. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology. 1995;22:1399-403. doi: 10.1016/0270–9139(95)90143-4
38. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012;28(2):159-65. doi: 10.1097/MOG.0b013e32834e7b4b
39. Csak T, Velayudham A, Hritz I, Petrasek J, Levin L, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E, Szabo G. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2001;300(3):433-41. doi: 10.1152/ajpgi.00163.2009
40. Селиверстов П., Радченко В., Сафроненкова И., Ситкин С. Взаимоотношения печени и кишечника на фоне дисбаланса микрофлоры толстой кишки. Врач. 2009;(10):27-31 [Seliverstov P, Radchenko V, Safronenkova I, Sitkin S. Liver-intestine relationships in colonic microflora dysbalance. Vrach. 2009;(10):27-31 (In Russ.)].
41. Вахрушев Я.М., Лукашевич А.П. Особенности нарушений пищеварения, всасывания и микробиоценоза в кишечнике у больных желчнокаменной болезнью. Терапевтический архив. 2017;(2):28-32 [Vakhrushev YaM, Lukashevich АР. Specific features of impaired intestinal digestion, absorption, and microbiocenosis in patients with cholelithiasis. Therapeutic Archive. 2017;(2):28-32 (In Russ.)]. doi: 10.17116/terarkh201789228-32
43. Al-Attas O, Al-Daghri N, Al-Rubeaan K. Changes in endotoxin levels in T2DM subjects on antidiabetic therapias. Cardiovasc Diabet. 2009;8:20-29. doi: 10.1186/1475-2840-8-20
44. Rodes N, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics Lactobacillus and Bifidobacteriumon gut-derived lypopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013;23:518-26. doi: 10.4014/jmb.1205.05018
45. Arumugam M, Raes J, Pelletier Е, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80. doi: 10.1038/nature09944
46. Селиверстов П.В., Ситкин С.И., Радченко В.Г. Роль дисбиоза кишечника в развитии митохондриальной дисфункции и неалкогольной жировой болезни печени. Медицинский совет. Гастроэнтерология. 2018;(6):90-5 [Seliverstov PV, Sitkin SI, Radchenko VG. The role of intestinal disbiosis in the development of mitochondrial dysfunction and nonalcoholic fatty liver disease. Meditsinskii sovet. Gastroenterologiya. 2018;(6):90-5 (In Russ.)]. doi: 10.21518/2079-701X-2018-6-89-95
47. Немцов Л.М. Синдром избыточного бактериального роста в кишечнике при заболеваниях печени. Здравоохранение. 2015;(4):26-34 [Nemtsov LM. Syndrome of bacteria overgrowth under liver diseases. Zdravookhranenie. 2015;(4):26-34 (In Russ.)].
48. Fuchs C, Claudel T, Trauner M. Bile acid-mediated control of liver triglycerides. Semin Liver Dis. 2013;33(4):330-42. doi: 10.1055/s-0033-1358520
49. Conradas VM, Jorens PJ, De Clerck LS, Van Saene HK, Ieven MM, Bosmans JM, Schuerwegh A, Bridts CH, Wuyts F, Stevens WJ, Anker SD, Rauchhaus M, Vrints CJ. Selectiv intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail. 2004;6(4):483-91. doi: org/10.1016/j.ejheart.2003.12.004
50. Вахрушев Я.М., Горбунов А.Ю., Тронина Д.В., Сучкова Е.В., Ляпина М.В., Хохлачева Н.А. Желчнокаменная болезнь как возможное проявление системной патологии органов пищеварения. Терапевтический архив. 2015;87(2):54-8 [Vakhrushev YaM, Gorbunov AYu, Tronina DV, Suchkova EV, Liapina MV, Khokhlacheva NA. Cholelithiasis as a possible manifestation of systemic digestive diseases. Therapeutic Archive. 2015;87(2):54-8 (In Russ.)]. doi: 10.17116/terarkh201587254-58
51. Hylemon PB, Zhou HP, Pandak WM, Ren SL, Git G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50(8):1509-20. doi: 10.1194/jlr.R900007-JLR200
52. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor – A molecular link between bile acid and glucose metabolism. Arterioscler Thromb Vasc. 2005;25(10):2020-31. doi: 10.1161/01.ATV.0000178994.21828.a7
53. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1-2):17-29. doi: 10.1061/j.mce.2012.05.004
54. Sayin SI, Wahlstrom A, Felin J, Jantty S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the levels of Tauro-β-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab. 2013;368(1-2):17-29. doi: 10.1061/j.cmet.2013.01.003
55. Li F, Jiang CT, Krauze KW, Li YF, Albert I, Hao HP, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodeling leads tu inhibition of intestinal farnesoid X receptor signaling and decreased obesity. Nat Commun. 2013;4:2384. doi: 10.1038/ncomms.3384
56. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci. 2006;103(4):1006-11. doi: 10.1073/pnas.0506982103
57. Маевская Е.А., Черемушкин С.В., Кривобородова Н.А., Кучерявый Ю.А. Синдром избыточного бактериального роста в тонкой кишке: от последних научных данных к рутинной практике. Клинические перспективы гастроэнтерологии, гепатологии. 2013;(5):29-40 [Mayevskaya YeA, Cheremushkin SV, Krivoborodova NA, Kucheryavy YuA. Small-intestinal bacterial overgrowth syndrome: from recent scientific data to everyday practice. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2013;(5):29-40 (In Russ.)].
58. Ильченко А.А. Болезни желчного пузыря и желчных путей: руководство для врачей. М.: МИА, 2011 [Il'chenko A.A. Diseases of the gallbladder and biliary tract: a guide for physicians. Moscow: MIA, 2011 (In Russ.)].
59. Вахрушев Я.М., Лукашевич А.П., Горбунов А.Ю., Пенкина И.А. Интестинальные механизмы в нарушении энтерогепатической циркуляции желчных кислот при желчнокаменной болезни. Вестник Российской академии медицинских наук. 2017;72(2):105-11 [Vakhrushev YaM, Lukashevich AP, Gorbunov AYu, Penkina IA. Intestinal Mechanisms of Enterohepatic Circulation Disturbance of Bile Acids in Cholelithiasis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2017;72(2):105-11 (In Russ.)]. doi: 10.15690/vramn807
60. Савельев В.С., Петухов В.А. Желчнокаменная болезнь и синдром нарушенного пищеварения. М.: Боргес, 2011 [Savel'ev VS, Petukhov VA. Gallstone disease and indigestion syndrome. Moscow: Borges, 2011 (In Russ.)].
61. Чукаева И.И., Самородская И.В., Ларина В.Н. Сочетанная патология: дискуссионные вопросы терминологии, учета и влияния на выбор тактики ведения пациента. Терапевтический архив. 2018;90(8):125-30 [Chukayeva II, Samorodskaya IV, Larina VN. The prevalence of multimorbidity: discussion about the terminology, registration and its effect on patient’s health care utilization. Therapeutic Archive. 2018;90(8):125-30 (In Russ.)]. doi: 10.26442/terarkh2018908125-130
________________________________________________
2. [Ivashkin VT, Mayevskaya MV, Pavlov ChS. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2012;(1):3-9 (In Russ.)].
3. De Alwis NM, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(1):104-12. doi: 10.1016/j.jhep.2008.01.009
4. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:6891. doi: 10.1136/bmj.d6891
5. Tacuma Y, Nouso Y. Nonalcoholic steatohepatitis associated hepatocellular carcinoma: our case series and literature review. Wld J Gastroenterol. 2010;16(12):1436-41. doi: 10.3748/wjg.v16.i12.1436
6. Waly RS, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus of different aspects of management. ISRN Oncol. 2012;2012:1-12. doi: 10.5402/2012/421673
7. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342. doi: 10.1016/ j.cgh.2012.10.001
8. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24(4):899-919. doi: 10.1016/j.idc.2010.07.004
9. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371. doi: 10.1016/j.jhep.2009.03.019
10. McCullough AJ. The epidemiology and risk factors of NASH. Hepatology. 2013;58(5):1644-54. doi: 10.1002/9780470987438.ch3
11. Duvnjak M, Lerotic I, Barsic N. Patogenesis and management issues for non-alcoholik fatty liver disease. World J Gastroenterol. 2007;13(34):4539-50. doi: 10.3748/wjg.v13.i34.4539
12. Atabek ME. Non-alcoholic fatty liver disease and metabolic syndrome in obese children. J Gastroenterol. 2011;17(39):4445. doi: 10.3748/wjg.v17.i39.4445
13. Ahmed A, Perumpail RB, Harrison SA. Hige prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? Hepatology. 2016;63(1):20-2. doi: 10.1002/hep.28277
14. Gerskowitch VP, Hodge J, Hull RAD, Shankley NP, Kalindjian SB, McEwen J, Black JW. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol. 2007;63(5):618-22. doi: 10.1111/j.1365-2125.2006.02789.x
15. Williamson RM, Price JF, Glance S, Perry E, Nee LD, Hayes PC, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-44. doi: 10.2337/dc10-2229
16. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hoffich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015;43(1):83-95. doi: 10.1111/apt.13405
17. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Kechagias S, Hultcrantz R. Fibrosis Stage is the strongest predictor for disease-specific mortality in NAFLD After Up to 33 Years of Follow-Up. Hepatology. 2015;61(5):1547-54. doi: 10.1016/j.jhep.2015.11.004
18. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progress tu hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436-43. doi: 10.1002/ijc.25797
19. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-90. doi: 10.1038/nrgastro.2013.171
20. Michelotti GA, Machado MV. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-60. doi: 10.1038/nrgastro.2013.183
21. Stickel F, Hellerbrand С. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303-7. doi: 10.1136/gut.2009.199661
22. [Podymova SD. Liver disease: a guide for physicians. 5th ed. Moscow: MIA, 2018 (In Russ.)].
23. Younossi ZM, Koenig AB, Abdelatif DA, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assement of prevalence, incidence and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
24. Copaci I, Mindrut E, Micu L, Hortopan M, Voiculescu M. Can disease progression in non-alcoholic steatohepatitis be stopped? J Hepatol. 2009;50(1):S358. doi: 10.1016/s0168-8278(09)60989-2
25. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381
26. Rolfe LD. Interactions among microorganisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis. 1984;6(1):73-9. doi: 10.1093/clinids/6.Supplement_1.S73
27. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fang SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-7. doi: 10.1002/hep.26319
28. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2012;57:601-9. doi: 10.1002/hep.26093
29. Erejuwa OO, Sulaiman SA, Wahab MSW. Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci. 2014;15:4158-88. doi: 10.3390/ijms15034158
30. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germfree mice. Proc Natl Acad Sci USA. 2007;104:979-84. doi: 10.1073/pnas.0605374104
31. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumor necrosis factor-alfa in a pathogenesis of nonalcoholic steatohepatitis. Gut. 2001;48:206-11. doi: 10.1136/gut.48.2.206
32. Wieland A, Frank DN, Harnke B, Bambha A. Systematic review: microbial dysbiosis and nonalcoholic fatty liver desease. Aliment Pharmacol Ther. 2015;42(9):1051-63. doi: 10.1111/apt.13376
33. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29(3):264-70. doi:10.1097/mog.0b013e32835ff948
34. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One. 2012;7(10):e47713. doi: 10.1371/journal.pone.0047713
35. Rivera CA, Adegboyega PN, van Rooijen N, Tagalicud A., Allman M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47(4):571-9. doi: 1016/j.hep.2007.04/019
36. Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. Curr Opin Lipidol. 2008;19(3):223-34. doi: 10.1097/MOL.0b013e3282fee935
37. Buchman AL, Dubin MD, Moucarzel AA, Jenden DJ, Roch M, Rice KM, Gornbein J, Ament ME. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology. 1995;22:1399-403. doi: 10.1016/0270–9139(95)90143-4
38. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012;28(2):159-65. doi: 10.1097/MOG.0b013e32834e7b4b
39. Csak T, Velayudham A, Hritz I, Petrasek J, Levin L, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E, Szabo G. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2001;300(3):433-41. doi: 10.1152/ajpgi.00163.2009
40. [Seliverstov P, Radchenko V, Safronenkova I, Sitkin S. Liver-intestine relationships in colonic microflora dysbalance. Vrach. 2009;(10):27-31 (In Russ.)].
41. [Vakhrushev YaM, Lukashevich АР. Specific features of impaired intestinal digestion, absorption, and microbiocenosis in patients with cholelithiasis. Therapeutic Archive. 2017;(2):28-32 (In Russ.)]. doi: 10.17116/terarkh201789228-32
43. Al-Attas O, Al-Daghri N, Al-Rubeaan K. Changes in endotoxin levels in T2DM subjects on antidiabetic therapias. Cardiovasc Diabet. 2009;8:20-29. doi: 10.1186/1475-2840-8-20
44. Rodes N, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics Lactobacillus and Bifidobacteriumon gut-derived lypopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013;23:518-26. doi: 10.4014/jmb.1205.05018
45. Arumugam M, Raes J, Pelletier Е, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80. doi: 10.1038/nature09944
46. [Seliverstov PV, Sitkin SI, Radchenko VG. The role of intestinal disbiosis in the development of mitochondrial dysfunction and nonalcoholic fatty liver disease. Meditsinskii sovet. Gastroenterologiya. 2018;(6):90-5 (In Russ.)]. doi: 10.21518/2079-701X-2018-6-89-95
47. [Nemtsov LM. Syndrome of bacteria overgrowth under liver diseases. Zdravookhranenie. 2015;(4):26-34 (In Russ.)].
48. Fuchs C, Claudel T, Trauner M. Bile acid-mediated control of liver triglycerides. Semin Liver Dis. 2013;33(4):330-42. doi: 10.1055/s-0033-1358520
49. Conradas VM, Jorens PJ, De Clerck LS, Van Saene HK, Ieven MM, Bosmans JM, Schuerwegh A, Bridts CH, Wuyts F, Stevens WJ, Anker SD, Rauchhaus M, Vrints CJ. Selectiv intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail. 2004;6(4):483-91. doi: org/10.1016/j.ejheart.2003.12.004
50. [Vakhrushev YaM, Gorbunov AYu, Tronina DV, Suchkova EV, Liapina MV, Khokhlacheva NA. Cholelithiasis as a possible manifestation of systemic digestive diseases. Therapeutic Archive. 2015;87(2):54-8 (In Russ.)]. doi: 10.17116/terarkh201587254-58
51. Hylemon PB, Zhou HP, Pandak WM, Ren SL, Git G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50(8):1509-20. doi: 10.1194/jlr.R900007-JLR200
52. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor – A molecular link between bile acid and glucose metabolism. Arterioscler Thromb Vasc. 2005;25(10):2020-31. doi: 10.1161/01.ATV.0000178994.21828.a7
53. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1-2):17-29. doi: 10.1061/j.mce.2012.05.004
54. Sayin SI, Wahlstrom A, Felin J, Jantty S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the levels of Tauro-β-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab. 2013;368(1-2):17-29. doi: 10.1061/j.cmet.2013.01.003
55. Li F, Jiang CT, Krauze KW, Li YF, Albert I, Hao HP, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodeling leads tu inhibition of intestinal farnesoid X receptor signaling and decreased obesity. Nat Commun. 2013;4:2384. doi: 10.1038/ncomms.3384
56. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci. 2006;103(4):1006-11. doi: 10.1073/pnas.0506982103
57. [Mayevskaya YeA, Cheremushkin SV, Krivoborodova NA, Kucheryavy YuA. Small-intestinal bacterial overgrowth syndrome: from recent scientific data to everyday practice. Klinicheskie Perspektivy Gastroenterologii, Gepatologii. 2013;(5):29-40 (In Russ.)].
58.[Il'chenko A.A. Diseases of the gallbladder and biliary tract: a guide for physicians. Moscow: MIA, 2011 (In Russ.)].
59. [Vakhrushev YaM, Lukashevich AP, Gorbunov AYu, Penkina IA. Intestinal Mechanisms of Enterohepatic Circulation Disturbance of Bile Acids in Cholelithiasis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2017;72(2):105-11 (In Russ.)]. doi: 10.15690/vramn807
60. [Savel'ev VS, Petukhov VA. Gallstone disease and indigestion syndrome. Moscow: Borges, 2011 (In Russ.)].
61. [Chukayeva II, Samorodskaya IV, Larina VN. The prevalence of multimorbidity: discussion about the terminology, registration and its effect on patient’s health care utilization. Therapeutic Archive. 2018;90(8):125-30 (In Russ.)]. doi: 10.26442/terarkh2018908125-130
Авторы
Я.М. Вахрушев, Е.В. Сучкова, А.П. Лукашевич
ФГБОУ ВО «Ижевская государственная медицинская академия» Минздрава России, Ижевск, Россия
Izhevsk State Medical Academy, Izhevsk, Russia
ФГБОУ ВО «Ижевская государственная медицинская академия» Минздрава России, Ижевск, Россия
________________________________________________
Izhevsk State Medical Academy, Izhevsk, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.